[Federal Register Volume 74, Number 174 (Thursday, September 10, 2009)]
[Notices]
[Pages 46578-46579]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-21744]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel Meeting

AGENCY: Department of Defense, Assistant Secretary of Defense (Health 
Affairs).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (5 U.S.C., Appendix, as amended) and the Government in the 
Sunshine Act of 1976 (5 U.S.C. 552b, as amended) the Department of 
Defense announces that the Uniform Formulary Beneficiary Advisory Panel 
(hereafter referred to as the Panel) will meet to review and comment on 
recommendations made to the Director, TRICARE Management Activity, by 
the Pharmacy and Therapeutics Committee regarding the Uniform 
Formulary.
    Due to scheduling difficulties the Uniform Formulary Beneficiary 
Advisory Panel was unable to finalize its agenda in time to publish 
notice of its meeting in the Federal Register for the 15 calendar days 
required by 41 CFR 102-3.150(a). Accordingly, the Committee Management 
Officer for the Department of Defense, pursuant to 41 CFR 102-3.150(b), 
waives the 15 calendar-day notification requirement.

DATES: The meeting will be held September 24, 2009, from 8 a.m. to 5 
p.m. and is open to the public, but seating is limited. The panel will 
also conduct an Administrative Work Meeting from 7 a.m. to 8 a.m. that 
is closed to the public.

ADDRESSES: The meetings will be held at the Naval Heritage Center 
Theater, 701 Pennsylvania Avenue, NW., Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Lieutenant Colonel Thomas Bacon, 
Designated Federal Officer, Uniform Formulary Beneficiary Advisory 
Panel, Skyline 5, Suite 810, 5111 Leesburg Pike, Falls Church, VA 
22041-3206; (703) 681-2890 (phone), (703) 681-1940 (fax), e-mail: 
<a href="/cdn-cgi/l/email-protection#57153627253226223224232417233a3679382433793a3e3b"><span class="__cf_email__" data-cfemail="61230011130410140412151221150c004f0e12054f0c080d">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: 

Meeting Accessibility

    Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102-3.140 through 
102-3.165, and the availability of space this meeting is open to the 
public. Seating is limited and will be provided only to the first 220 
people signing in. All persons must sign in legibly.

Meeting Agenda

    Sign-In; Welcome and Opening Remarks; Public Citizen Comments; 
Scheduled Therapeutic Class Reviews--Phosphodiesterase-5 Inhibitors and 
New Drugs in Previously Reviewed Classes; Drugs recommended for non-
formulary placement due to non-compliance with 2008 NDAA Section 703; 
Panel Discussions and Vote, and comments following each therapeutic 
class review.

Administrative Work Meeting

    Prior to the public meeting the Panel will conduct an 
Administrative Work Meeting from 7 a.m. to 8 a.m. to discuss 
administrative matters of the Panel. Pursuant to 41 CFR 102-3.160, the 
Administrative Work Meeting will be closed to the public.

Written Statements

    Pursuant to 41 CFR 102-3.105(j) and 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel at any time or in response to the stated agenda 
of a planned meeting.

[[Page 46579]]

Written statements should be submitted to the Panel's Designated 
Federal Officer; the Designated Federal Officer's contact information 
can be obtained from the General Services Administration's Federal 
Advisory Committee Act Database at https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting then 
these statements must be submitted no later than five business days 
prior to the meeting in question. The Designated Federal Officer will 
review all submitted written statements and provide copies to all the 
committee members.

Public Comments

    In addition to written statements, the Panel will set aside 1 hour 
for individual or interested groups to address the Panel. To ensure 
consideration of their comments, individuals and interested groups 
should submit written statements as outlined in this notice, but if 
they still want to address the Panel then they will be afforded the 
opportunity to register to address the Panel. The Panel's Designated 
Federal Officer will have a ``Sign Up Roster'' available at the Panel 
meeting, for registration on a first-come, first-serve basis. Those 
wishing to address the Panel will be given no more than 5 minutes to 
present their comments, and at the end of the 1-hour time period no 
further public comments will be accepted. Anyone who signs up to 
address the Panel but is unable to do so due to the time limitation may 
submit their comments in writing; however, they must understand that 
their written comments may not be reviewed prior to the Panel's 
deliberation. Accordingly, the Panel recommends that individuals and 
interested groups consider submitting written statements instead of 
addressing the Panel.

    Dated: September 3, 2009.
Patricia L. Toppings,
OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. E9-21744 Filed 9-9-09; 8:45 am]
BILLING CODE 5001-06-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>